dr. lenz on the benefit of regorafenib in crc
Published 5 years ago • 299 plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
1:13
dr. lenz on breakthrough designation of encorafenib, binimetinib, and cetuximab in braf crc
-
1:27
dr. lenz on later-line combo approaches in crc
-
11:24
managing toxicities associated with regorafenib
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
1:16
dr. eng on roles of regorafenib and tas-102 in crc treatment
-
5:31
practical advice for using regorafenib
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
2:04
dr. lenz on the changing landscape of metastatic colorectal cancer
-
4:10
lenz: stivarga (regorafenib) treatment, dosing strategies
-
1:28
dr. overman on distinctions between regorafenib and tas-102 in crc
-
1:49
dr. george demetri describes the mechanism of action of regorafenib in gist
-
3:53
regorafenib in colorectal cancer: optimizing the dose
-
1:19
dr. lenz on need for new treatment strategies in colorectal cancer
-
6:33
patient selection for regorafenib in crc
-
9:34
regorafenib in colorectal cancer
-
1:00
dr. lenz on next steps with immunotherapy in mcrc
-
0:57
dr. bekaii-saab discusses the next steps with regorafenib in crc
-
1:20
dr. bekaii-saab on the use of regorafenib in patients with mcrc